BACE inhibitors and their use in the treatment of Alzheimer's Disease BACE (²-site of APP cleaving enzyme) is a critical component in Alzheimer's Disease (AD), and the development of BACE inhibitors shows great potential as a therapy for the disease. BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease covers virtually all aspects of BACE from initial identification, discovery of inhibitors, and challenges in clinical development, while providing a global understanding essential for productive and successful drug discovery. This book details the story of the discovery of BACE and its role in AD and comprehensively discusses: * The development of BACE inhibitors as therapeutics for Alzheimer's disease * The research that led to the identification of BACE * New BACE inhibitors currently being clinically tested * ADME (absorption, distribution, metabolism, excretion) and clinical trial design--topics not addressed in current field literature * Cutting-edge technology such as high-throughput screening, structure-based drug design, and QSAR in context of BACE inhibitors and Alzheimer's drug discovery * Other approaches to BACE inhibition based on interaction with the precursor protein APP By enhancing the reader's understanding of the various aspects of the BACE drug-discovery process, this much-needed reference will serve as a key resource for all scientists involved in Alzheimer's research--and inspire new approaches to treatment of AD. Note: CD-ROM/DVD and other supplementary materials are not included as part of eBook file.